文献・資料をご希望の際は、資料請求ページの備考欄に見出し番号（下記リストの赤色の数字）を入力の上、ご連絡ください。
245
Urinary L-FABP: A Novel Biomarker for Evaluating Diabetic Nephropathy Onset and Progression. A Narrative Review.
Diabetes Ther. 2025.
doi: 10.1007/s13300-025-01731-w.PubMed
doi: 10.1007/s13300-025-01731-w.PubMed
242
Development of a multiple urinary biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy.
BMC Nephrol. 2025.
doi: 10.1186/s12882-025-04049-8.PubMed
doi: 10.1186/s12882-025-04049-8.PubMed
237
Estimated Proximal Tubule Fluid Phosphate Concentration and Renal Tubular Damage Biomarkers in Early Stages of Chronic Kidney Disease.
235
Topiroxostat-A Safer Uricostatic Drug with Enhanced Renal Protection: A Narrative Review.
234
Diagnostic Accuracy of L-FABP-to-Creatinine Ratio (LCR) for Prediction of Kidney Damage in Type-2 DM Patients Taking Albumin-to-Creatinine Ratio (ACR) as Gold Standard.
232
Development of Liver Fibrosis Represented by the Fibrosis-4 Index Is a Specific Risk Factor for Tubular Injury in Individuals with Type 2 Diabetes.
Biomedicines. 2024
doi: 10.3390/biomedicines12081789. PubMed
doi: 10.3390/biomedicines12081789. PubMed
231
Estimated proximal tubule fluid phosphate concentration and renal tubular damage biomarkers in early stages of chronic kidney disease.
J Ren Nutr. 2024
doi: 10.1053/j.jrn.2024.06.009.PubMed
doi: 10.1053/j.jrn.2024.06.009.PubMed
226
Evaluation of Urinary L-FABP as a Tubular Damage Marker in Pediatric Neurogenic Bladder-A Pilot Study.
J Clin Med. 2024
doi: 10.3390/jcm13030736.PubMed
doi: 10.3390/jcm13030736.PubMed
224
Comparison of Urinary Liver Fatty Acid Binding Protein Level and Pathologic Biopsy Findings 1 Year After Kidney Transplantation.
Transplant Proc. 2024
doi: 10.1016/j.transproceed.2023.12.016.PubMed
doi: 10.1016/j.transproceed.2023.12.016.PubMed
218
Urinary Liver-Type Fatty Acid Binding Protein, a Biomarker for Disease Progression, Dialysis and Overall Mortality in Chronic Kidney Disease.
J Pers Med. 2023
doi: 10.3390/jpm13101481.PubMed
doi: 10.3390/jpm13101481.PubMed
214
Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes.
Biomedicines. 2023
doi: 10.3390/biomedicines11113020.PubMed
doi: 10.3390/biomedicines11113020.PubMed
211
Elevated urinary angiotensinogen excretion links central and renal hemodynamic alterations.
Sci Rep. 2023
doi: 10.1038/s41598-023-38507-wPubMed
doi: 10.1038/s41598-023-38507-wPubMed
210
Association of urinary liver-type fatty acid-binding protein with outcomes after adrenalectomy for unilateral primary aldosteronism.
Clin Chim Acta. 2023
doi: 10.1016/j.cca.2023.117465.PubMed
doi: 10.1016/j.cca.2023.117465.PubMed
207
Increased urinary albumin leakage is related to injuries of glomerular glycocalyx and podocytes, and associated with tubular dysfunction in preeclampsia.
Pregnancy Hypertens. 2023PubMed
206
Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.
J Am Heart Assoc. 2023PubMed
205
Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.
Int Urol Nephrol. 2023PubMed
203
Clinical utility of tubular markers in kidney disease: a narrative review.
J Lab Precis Med. 2022JLPM
200
Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis.
Front Med (Lausanne). 2022PubMed
199
Effects of dietary phosphorus concentration and phosphate salt form on renal tubule function in unilateral nephrectomized rats .
Nutr Health. 2022PubMed
196
Early, Noninvasive Clinical Indicators of Kidney Prognosis in Primary Nephrotic Syndrome: A Retrospective Exploratory Study .
Int J Nephrol. 2022PubMed
190
Biomarkers for the early prediction of contrast-induced nephropathy after percutaneous coronary intervention in adults: A systematic review and meta-analysis.
Angiology. 2022PubMed
189
Usefulness of urinary tubule injury markers for predicting progression of renal dysfunction in patients with type 2 diabetes and albuminuria: The Fukuoka Diabetes Registry.
Diabetes Res Clin Pract. 2022PubMed
182
Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.
Tohoku J Exp Med. 2021PubMed
179
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.
J Diabetes Res. 2021
doi: 10.1155/2021/7382620. PubMed
doi: 10.1155/2021/7382620. PubMed
178
Exercise Ameliorates Diabetic Kidney Disease in Type 2 Diabetic Fatty Rats.
Antioxidants (Basel). 2021PubMed
176
Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs.
J Vet Med Sci. 2021PubMed
174
Amniotic Fluid L-Type Fatty Acid-Binding Protein in Predicting Fetal Condition.
Tohoku J Exp Med. 2021PubMed
168
Renal hemodynamics across the adult lifespan: Relevance of flow pulsatility to chronic kidney disease.
Exp Gerontol. 2021
doi: 10.1016/j.exger.2021.111459. PubMed
doi: 10.1016/j.exger.2021.111459. PubMed
166
Relationship of urinary liver-type fatty acid-binding protein with cardiovascular risk factors in the Japanese population without chronic kidney disease: Sasayama study.
BMC Nephrol. 2021
doi: 10.1186/s12882-021-02398-8. PubMed
doi: 10.1186/s12882-021-02398-8. PubMed
165
Preliminary study of urinary excretion of liver-type fatty acid-binding protein in a cat model of chronic kidney disease.
Can J Vet Res. 2021PubMed
164
Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients.
J Med Biochem. 2020
doi: 10.2478/jomb-2019-0037. PubMed
doi: 10.2478/jomb-2019-0037. PubMed
163
Liver-type fatty acid-binding protein and neutrophil gelatinase-associated lipocalin in cats with chronic kidney disease and hyperthyroidism.
J Vet Intern Med. 2021
doi: 10.1111/jvim.16074. PubMed
doi: 10.1111/jvim.16074. PubMed
162
Predictive value of novel biomarkers for chronic kidney disease among workers occupationally exposed to silica.
Toxicol Ind Health. 2021
doi: 10.1177/0748233721990304. PubMed
doi: 10.1177/0748233721990304. PubMed
161
Urinary liver-type fatty acid-binding protein is a predictor of mortality in individuals with type 2 diabetes.
Diabet Med. 2021
doi: 10.1111/dme.14527.PubMed
doi: 10.1111/dme.14527.PubMed
160
Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
Clin Exp Nephrol. 2021
doi: 10.1007/s10157-020-02007-2.PubMed
doi: 10.1007/s10157-020-02007-2.PubMed
158
Urinary Liver-type Fatty Acid-Binding Protein Predicts Residual Renal Function Decline in Peritoneal Dialysis Patients.
Med Sci Monit. 2020PubMed
157
Novel Urinary Biomarkers and Chronic Kidney Disease After Coronary Angiography: A Prospective Case-Controlled Study.
Open Access Maced J Med Sci. 2020OAMJMS
154
Longitudinal kidney injury biomarker trajectories in children with obstructive uropathy.
Pediatr Nephrol. 2020PubMed
152
Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Major Adverse Cardiovascular Events in Patients with Hypertension.
Am J Hypertens. 2020PubMed
151
Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease.
J Vet Intern Med. 2020PubMed
149
Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats.
J Diabetes Res. 2020Hindawi
148
Effects of exercise on residual renal function in patients undergoing peritoneal dialysis: a post-hoc analysis of a randomized controlled trial.
Ther Apher Dial. 2020PubMed
146
Evaluation of liver-type fatty acid binding protein (L-FABP) and interleukin 6 in children with renal cysts.
Adv Clin Exp Med. 2019PubMed
145
The influence of renal function by ibuprofen treatment for patent ductus arteriosus in extremely low-birth-weight infants.
Pediatr Int. 2019PubMed
144
The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats.
Kidney Blood Press Res. 2019PubMed
140
Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary β2 microglobulin levels: a retrospective observational study.
J Pharm Health Care Sci. 2019PubMed
139
Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice.
Hypertens Res. 2019PubMed
138
Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study.
Diabetol Int. 2018PubMed
137
Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease.
Kidney Blood Press Res. 2018PubMed
134
Urinary liver-type fatty acid-binding protein levels as a potential risk factor for renal dysfunction in male HIV-infected Japanese patients receiving antiretroviral therapy: a pilot study.
Int J STD AIDS. 2018PubMed
130
Urinary L-FABP level in children with nephrotic syndrome and tubular dysfunction.
Pediatr Int. 2018PubMed
129
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucoselowering-independent manner.
BMJ Open Diabetes Res Care. 2017PubMed
127
Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography.
QJM. 2018PubMed
126
Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.
Hypertens Res. 2017PubMed
125
Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.
Eur J Pharmacol. 2017PubMed
124
Urinary liver-type fatty acid-binding protein is associated with subendocardial viability ratio in middle- and older-aged adults.
Clin Exp Hypertens. 2017PubMed
121
Urine liver fatty acid binding protein and chronic kidney disease progression.
Scand J Clin Lab Invest. 2017PubMed
120
Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes.
Diabetologia. 2017 PubMed
119
Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes.
JClin Med Res. 2017PubMed
116
Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion.
Nephrology. 2017PubMed
113
The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.
Clin Exp Nephrol. 2016PubMed
111
Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.
FASEB J. 2016PubMed
107
Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.
Cardiovasc Diabetol. 15(1): 76, 2016.PubMed
106
Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury.
Am J Physiol Renal Physiol. 310(11):F1366-1376, 2016.PubMed
104
Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease.
Clin Chem Lab Med. 2016.PubMed
102
Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD.
Clin Exp Nephrol. 20(2): 195-203, 2016.PubMed
99
Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes.
Pediatr Nephrol. 31(4):623-631, 2016.PubMed
96
Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats.
Physiol Rep. 3(12), 2015.PubMed
95
Urinary liver-type fatty acid-binding protein change in gestational diabetes mellitus.
Diabetes Res Clin Pract. 109(3): e36-e38, 2015.PubMed
94
Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study.
Clin J Am Soc Nephrol. 10(11):1956-1963, 2015.PubMed
91
Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.
Scand J Clin Lab Invest. 75(5): 421-427, 2015.PubMed
89
Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?
Nephrology. 10(4):e0122212, 2015.PubMed
88
Distinct roles of urinary liver-type Fatty Acid-binding protein in non-diabetic patients with anemia.
PLoS One. 10(5): e0126990, 2015.PubMed
87
Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy.
PLoS One. 10(4): e0122212, 2015.PubMed
85
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Clin Exp Nephrol. 19(6): 1044-1053, 2015.PubMed
84
Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus.
Diabetologia. 58(1): 188-198, 2015.PubMed
81
LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: a retrospective analysis.
Diabetes Res Clin Pract. 106(2): 241-246, 2014.PubMed
80
NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.
Clin Chem Lab Med. 52(4): 537-546, 2014.PubMed
74
Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women’s Interagency HIV Study (WIHS).
HIV Med. 15(5): 291-300, 2014.PubMed
72
Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2.
Heart Vessels. 30(3): 362-368, 2014.PubMed
71
Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.
Diabetes Metab Res Rev. 30(8): 736-741, 2014.PubMed
70
Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.
AIDS Res Hum Retroviruses. 30(4): 363-369, 2014.PubMed
63
Moderate-intensity single exercise session does not induce renal damage.
J Clin Lab Anal. 27(3): 177-180, 2013.PubMed
62
A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.
Am J Physiol Renal Physiol. 305(12): F1796-1803, 2013.PubMed
60
Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy.
Diabetes Care. 36(5): 1248-1253, 2013.PubMed
58
Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Diabet Med. 29(8): e184-190, 2012.PubMed
56
Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
Hypertens Res. 35(11): 1058-1062, 2012.PubMed
51
Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).
Internal Medicine. 50(12): 1273-1278, 2011.PubMed
50
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Hypertens Res . 34: 935-941, 2011.PubMed
48
Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.
Nephrol Dial Transplant. 26(7): 2127-2137, 2011.PubMed
45
Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.
Nephrol Dial Transplant. 26(11): 3465-3473, 2011.PubMed
44
Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients.
Diabetes Care. 34(3): 691-696, 2011.PubMed
41
Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.
Eur J Clin Invest. 40(2): 95-102, 2010.PubMed
40
Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.
Diabetes Care. 33(6): 1320-1324, 2010.PubMed
39
Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.
Am J Med Sci. 339(2): 157-163, 2010.PubMed
38
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Kidney Blood Press Res. 33(3): 213-220, 2010.PubMed
37
Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
Eur J Clin Invest. 40(9): 790-796, 2010.PubMed
34
Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.
Nephron Clin Pract. 112(3): c148-156, 2009.PubMed
33
Tubular and glomerular injury in diabetes and the impact of ACE inhibition.
Diabetes Care. 32(9): 1684-1688, 2009.PubMed
30
Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.
Metabolism. 58(8): 1185-1190, 2009.PubMed
29
Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice.
Nephrol Dial Transplant. 24(3): 788-800, 2009.PubMed
25
Renoprotective effect of telmisartan in patients with chronic kidney disease.
Clin Exp Hypertens. 30(7): 662-672, 2008.PubMed
24
Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.
Clin Nephrol. 70(5): 385-392, 2008.PubMed
21
Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.
Diabetologia. 50(2): 490-492, 2007.PubMed
20
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Am J Med Sci. 333(6): 321-326, 2007.PubMed
19
Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Am J Hypertens. 20(11): 1195-1201, 2007.PubMed
16
Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy.
Diabetes Care. 29(7): 1717, 2006.PubMed
15
Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.
Clin Nephrol. 65(1): 1-6, 2006.PubMed
14
Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.
Diabetes Metab Res Rev. 22(5): 385-389, 2006.PubMed
13
Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia.
Am J Nephrol. 26(3): 276-280, 2006.PubMed
12
Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
Am J Nephrol. 26(1): 82-86, 2006.PubMed
11
Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction.
Am J Pathol. 169(4): 1107-1117, 2006.PubMed
10
Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.
Mol Cell Biochem. 284(1-2): 175-182, 2006.PubMed
8
Clinical Significance of Urinary Liver-Type Fatty acid-binding Protein in Patients With Diabetic Nephropathy.
Diabetes Care. 28(18): 2038-2039, 2005.PubMed
7
Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.
TAm J Med Sci. 330(4): 161-165, 2005.PubMed
6
Effect of Pitavastatin on Urinary Liver-Type Fatty acid-binding Protein Levels in Patients With Early Diabetic Nephropathy.
Diabetes Care. 28(11): 2728-2732, 2005.PubMed
5
Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.
Am J Nephrol. 25(5): 447-450, 2005.PubMed
4
Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial.
J Lab Clin Med. 145(3): 125-133, 2005.PubMed
3
Urinary excretion of liver fatty acid-binding protein in health-check participants.
Clin Exp Nephrol. 9(1): 34-39, 2005.PubMed
2
Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.
Am J Pathol. 165(4): 1243-1255, 2004.PubMed
1
Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease.
J Lab Clin Med. 143(1): 23-30, 2004.PubMed
